CoChat

Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism

Open access
Stancu, Ilie-Cosmin, Vasconcelos, Bruno, Terwel, Dick, Dewachter, Ilse · 2014 · Molecular Neurodegeneration

The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.

Abstract

The amyloid cascade hypothesis has been the prevailing hypothesis in Alzheimer's Disease research, although the final and most wanted proof i.e. fully successful anti-amyloid clinical trials in patients, is still lacking. This may require a better in depth understanding of the cascade. Particularly, the exact toxic forms of Aβ and Tau, the molecular link between them and their respective contributions to the disease process need to be identified in detail. Although the lack of final proof has raised substantial criticism on the hypothesis per se, accumulating experimental evidence in in vitro models, in vivo models and from biomarkers analysis in patients supports the amyloid cascade and particularly Aβ-induced Tau-pathology, which is the focus of this review. We here discuss available models that recapitulate Aβ-induced Tau-pathology and review some potential underlying mechanisms. The availability and diversity of these models that mimic the amyloid cascade partially or more complete, provide tools to study remaining questions, which are crucial for development of therapeutic strategies for Alzheimer's Disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1326-9-51

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Amyloid cascade hypothesis in transgenic mice with combined amyloid and Tau pathology (left panel). Hippocampal (HC; CA1) and cortical (Cx) immunohistochemical staining for amyloid plaques (anti-Aβ, WO2), astrocytes (GFAP), microglia (Iba1), P-GSK3 (GSK3pT216/279), P-Tau (anti-pTau, AT-8) and NeuN for cortical/hippocampal atrophy (all images are 20×, except NeuN at 4×) is presented in transgenic mice expressing mutant APP/PS1 and mutant Tau [55]. These mice were generated by crossing mutant APP/PS1 and mutant Tau mice, respectively denoted as F+/T- (5xFAD; [59]) and F-/T+(TauP301S; [60]). Of note, AT-8 staining was optimized to match Gallyas silver staining patterns, hence representing NFTs (data not shown). Main pathological features found in F+/T+ mice (right panel). Immunolabeling with anti-Aβ (WO2), showing no changes in amyloid plaque load in the cortex of F+/T + and F+/T- mice (upper panel, 4× and 20×); Aggravation of Tau-pathology, anti-pTau (AT-8) staining (NFT), in hippocampal CA1 region and cortex of F+/T+ compared to F-/T+ parental strain transgenic mice (middle panel, 20×); anti-neuronal nuclear staining (NeuN) showing decreased cortical and hippocampal area in F+/T+ compared to F-/T- mice (lower panel, 4×).
Figure 1 Amyloid cascade hypothesis in transgenic mice with combined amyloid and Tau pathology (left panel). Hippocampal (HC; CA1) and cortical (Cx) immunohistochemical staining for amyloid plaques (anti-Aβ, WO2), astrocytes (GFAP), microglia (Iba1), P-GSK3 (GSK3pT216/279), P-Tau (anti-pTau, AT-8) and NeuN for cortical/hippocampal atrophy (all images are 20×, except NeuN at 4×) is presented in transgenic mice expressing mutant APP/PS1 and mutant Tau [55]. These mice were generated by crossing mutant APP/PS1 and mutant Tau mice, respectively denoted as F+/T- (5xFAD; [59]) and F-/T+(TauP301S; [60]). Of note, AT-8 staining was optimized to match Gallyas silver staining patterns, hence representing NFTs (data not shown). Main pathological features found in F+/T+ mice (right panel). Immunolabeling with anti-Aβ (WO2), showing no changes in amyloid plaque load in the cortex of F+/T + and F+/T- mice (upper panel, 4× and 20×); Aggravation of Tau-pathology, anti-pTau (AT-8) staining (NFT), in hippocampal CA1 region and cortex of F+/T+ compared to F-/T+ parental strain transgenic mice (middle panel, 20×); anti-neuronal nuclear staining (NeuN) showing decreased cortical and hippocampal area in F+/T+ compared to F-/T- mice (lower panel, 4×).CC BY · PubMed Central
Figure 2 Graphical representation of the regional distribution of amyloid plaques and NFTs in hippocampus and entorhinal cortex (upper panel, hippocampal-entorhinal connectivity map modified after Deng et al. [61]). Analysis of the relation between amyloid plaques (anti-Aβ, WO2, green) and Tau-pathology (anti-pTau, AT-8, red) in entorhinal cortex (lower left panel) and hippocampus (lower right panel) of F+/T+ transgenic mice, with details of the regional distribution of amyloid- and Tau-pathology for each of these regions.
Figure 2 Graphical representation of the regional distribution of amyloid plaques and NFTs in hippocampus and entorhinal cortex (upper panel, hippocampal-entorhinal connectivity map modified after Deng et al. [61]). Analysis of the relation between amyloid plaques (anti-Aβ, WO2, green) and Tau-pathology (anti-pTau, AT-8, red) in entorhinal cortex (lower left panel) and hippocampus (lower right panel) of F+/T+ transgenic mice, with details of the regional distribution of amyloid- and Tau-pathology for each of these regions.CC BY · PubMed Central
Figure 3 Schematic presentation of proposed mechanisms involved in Aβ-induced Tau-aggregation as discussed in this review (elements in panel I. and II. modified from Servier Medical Art; elements in panel III. modified from Jucker and Walker [76] , Thal et al. [75] , Braak and Braak [73] ).
Figure 3 Schematic presentation of proposed mechanisms involved in Aβ-induced Tau-aggregation as discussed in this review (elements in panel I. and II. modified from Servier Medical Art; elements in panel III. modified from Jucker and Walker [76] , Thal et al. [75] , Braak and Braak [73] ).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 131 references

Cited by

See all 269

Metadata

Authors
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I.
Affiliations
UCLouvain (BE)
Corresponding author
Dewachter, Ilse
Venue
Molecular Neurodegeneration
Published
2014-11-18
Volume
9
Issue
1
Pages
51-51
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2120402847
Cited by
256
References
131
Citations by year
2026: 8 · 2025: 17 · 2024: 15 · 2023: 27 · 2022: 20 · 2021: 24 · 2020: 33 · 2019: 19 · 2018: 27 · 2017: 22 · 2016: 32 · 2015: 12
FWCI
2.61
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion)
  • Document Server@UHasselt (UHasselt) (submittedVersion, cc-by)
Funders
  • European Commission (305299)
  • Fonds De La Recherche Scientifique - FNRS
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, amyloid hypothesis, amyloid-beta, tau pathology, animal models of Alzheimer's disease, in vitro model, in vivo models, disease mechanisms
MeSH terms
Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. https://app.cochat.ai/papers/10.1186/1750-1326-9-51
The paper
Stancu, I.-C., Vasconcelos, B., Terwel, D., & Dewachter, I. (2014). Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. Molecular Neurodegeneration. https://doi.org/10.1186/1750-1326-9-51

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.